MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/dom.14335

Медицинская библиотека · Diabetes, obesity & metabolism · 2021

Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial.

Haidar Ahmad, Yale Jean-Francois, Lovblom Leif Erik, Cardinez Nancy, Orszag Andrej, Falappa C Marcelo, Gouchie-Provencher Nikita, Tsoukas Michael A, El Fathi Anas, Rene Jennifer, Eldelekli Devrim, Lanctôt Sebastien O, Scarr Daniel, Perkins Bruce A

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАEquivalence TrialПеревод в очереди

Аннотация

AIM: To assess whether adding empagliflozin to closed-loop automated insulin delivery could reduce the need for carbohydrate counting in type 1 diabetes (T1D) without worsening glucose control.

MATERIALS AND

METHODS

In an open-label, crossover, non-inferiority trial, 30 adult participants with T1D underwent outpatient automated insulin delivery interventions with three random sequences of prandial insulin strategy days: carbohydrate counting, simple meal announcement (no carbohydrate counting) and no meal announcement. During each sequence of prandial insulin strategies, participants were randomly assigned empagliflozin (25 mg/day) or not, and crossed over to the comparator. Mean glucose for carbohydrate counting without empagliflozin (control) was compared with no meal announcement with empagliflozin (in the primary non-inferiority comparison) and simple meal announcement with empagliflozin (in the conditional primary non-inferiority comparison).

RESULTS

Participants were aged 40 ± 15 years, had 27 ± 15 years diabetes duration and HbA1c of 7.6% ± 0.7% (59 ± 8 mmol/mol). The system with no meal announcement and empagliflozin was not non-inferior (and thus reasonably considered inferior) to the control arm (mean glucose 10.0 ± 1.6 vs. 8.5 ± 1.5 mmol/L; non-inferiority p = .94), while simple meal announcement and empagliflozin was non-inferior (8.5 ± 1.4 mmol/L; non-inferiority p = .003). Use of empagliflozin on the background of automated insulin delivery with carbohydrate counting was associated with lower mean glucose, corresponding to a 14% greater time in the target range. While no ketoacidosis was observed, mean fasting ketones levels were higher on empagliflozin (0.22 ± 0.18 vs. 0.13 ± 0.11 mmol/L; p < .001).

CONCLUSIONS

Empagliflozin added to automated insulin delivery has the potential to eliminate the need for carbohydrate counting and improves glycaemic control in conjunction with carbohydrate counting, but does not allow for the elimination of meal announcement.

Для цитирования: Haidar Ahmad, Yale Jean-Francois, Lovblom Leif Erik, Cardinez Nancy, Orszag Andrej, Falappa C Marcelo, Gouchie-Provencher Nikita, Tsoukas Michael A, El Fathi Anas, Rene Jennifer, Eldelekli Devrim, Lanctôt Sebastien O, Scarr Daniel, Perkins Bruce A. Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial.. Diabetes, obesity & metabolism. 2021. DOI: 10.1111/dom.14335.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.